Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Index PharmaceuticalsIndex Pharmaceuticals

Index Pharmaceuticals

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

The Company’s lead asset is cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. In addition, InDex has a broad portfolio of other DNA based ImmunoModulatory Sequences (DIMS) in discovery stage, with the potential to be used in the treatment of various immunological diseases.

InDex is a pharmaceutical development company, which means that the Company develops compounds from pre-clinical through clinical phases, with the strategy to out license the compounds during late stage clinical development for the concluding development work, regulatory approval and commercialisation.

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

The Company’s lead asset is cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. In addition, InDex has a broad portfolio of other DNA based ImmunoModulatory Sequences (DIMS) in discovery stage, with the potential to be used in the treatment of various immunological diseases.

InDex is a pharmaceutical development company, which means that the Company develops compounds from pre-clinical through clinical phases, with the strategy to out license the compounds during late stage clinical development for the concluding development work, regulatory approval and commercialisation.

Image showing the InDex Pharmaceuticals Logo

Index Pharmaceuticals

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

The Company’s lead asset is cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. In addition, InDex has a broad portfolio of other DNA based ImmunoModulatory Sequences (DIMS) in discovery stage, with the potential to be used in the treatment of various immunological diseases.

InDex is a pharmaceutical development company, which means that the Company develops compounds from pre-clinical through clinical phases, with the strategy to out license the compounds during late stage clinical development for the concluding development work, regulatory approval and commercialisation.

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

The Company’s lead asset is cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. In addition, InDex has a broad portfolio of other DNA based ImmunoModulatory Sequences (DIMS) in discovery stage, with the potential to be used in the treatment of various immunological diseases.

InDex is a pharmaceutical development company, which means that the Company develops compounds from pre-clinical through clinical phases, with the strategy to out license the compounds during late stage clinical development for the concluding development work, regulatory approval and commercialisation.